Investors in pharma and auto stocks are anxious ahead of the April 2 deadline for US tariffs. Despite a 6% fall over three ...

India's pharmaceutical industry is urging its government to negotiate with Washington from a “position of power” on tariffs ...

The session highlighted existing policy support mechanisms and upcoming opportunities under the PRIP scheme aimed at ...

The move follows the approval from the National Company Law Tribunal (NCLT), New Delhi Bench. With this consolidation, the ...

U.S. President Trump imposes 25% tariff on auto imports, spotlight on pharma imports, Indian industry at risk.

Hetero Group founder, B Parthasaradhi Reddy, warns of potential US reciprocal tariffs on Indian pharmaceuticals, which could ...

India is deeply concerned about the effects of Trump’s global tariff strategy, set to take effect on April 2, which could ...

Pharma stocks are under significant selling pressure. Here is a detailed analysis on the top worries for the sector.

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

The industry needs to embrace innovation with technology towards novel drug development to remain relevant in the marketplace.

The Nippon India Pharma Fund - Growth has an AUM of 7637.04 crores & has delivered CAGR of 29.65% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.82%. The minimum ...